^
Association details:
| Biomarker: | EGFR wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Opdivo® Intravenous Infusion Approved for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Combination with Chemotherapy in Taiwan
Published date:
02/22/2023
Excerpt:
Ono Pharmaceutical...announced that Ono Pharma Taiwan Co., Ltd., a Taiwanese subsidiary of ONO, received the approval of Opdivo® (nivolumab) Intravenous Infusion ("Opdivo"), a human anti-human PD-1 monoclonal antibody, on February 21, 2023 in Taiwan from the Taiwan Food and Drug Administration (TFDA), for neoadjuvant treatment of adult patients with resectable (tumors ≥4cm or node positive) and without EGFR or ALK genomic tumor aberrations non-small cell lung cancer in combination with platinum-doublet chemotherapy.
Secondary therapy:
Chemotherapy
Source:
Title:
18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC
Excerpt:
...Have a histologically or cytologically confirmed diagnosis of stage IV, EGFR WT and EML4-ALK fusion negative NSCLC....
Trial ID:
Source:
Title:
Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
Excerpt:
...- Patients with EGFR wild-type NSCLC...
More C2 evidence
Source:
Title:
Immuno- and PD-L1 PET to predict response and toxicity during nivolumab treatment in NSCLC Immuno- en PD-L1 PET om de respons en toxiciteit tijdens nivolumab behandeling in niet-kleincellig longcarcinoom te voorspellen.
Excerpt:
...In order to be eligible to participate in this study, a subject must meet all of the following criteria:- Have a histologically or cytologically confirmed diagnosis of stage IV, EGFR WT and EML4-ALK fusion negative NCSLC and have received at least one line of platinum based doublet chemotherapy. ...
Trial ID:
Less C2 evidence
Source:
Title:
Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis
Published date:
10/30/2017
Excerpt:
Our objective was to assess the comparative effectiveness and tolerability of all second-line treatments for advanced NSCLC with wild-type or unknown status for EGFR by a systematic review and network meta-analysis....For OS, nivolumab was more effective than docetaxel (hazard ratio (HR) 0.69, 95% credible interval (CrI) 0.56–0.83), pemetrexed (0.67, 0.52–0.83), erlotinib (0.68, 0.53–0.86), and gefitinib (0.66, 0.53–0.83). Pembrolizumab, atezolizumab, and pemetrexed plus erlotinib were also significantly more effective than docetaxel, pemetrexed, erlotinib, and gefitinib.
DOI:
10.1186/s12916-017-0954-x
